Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00087490 · ClinicalTrials.gov registry record · Phase 4
Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)
A Phase 4 study of Skin/Soft Tissue Infections and Methicillin Resistant Staphylococcus Aureus (MRSA), sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 1,077
- Enrollment target
- 20
- Study locations
NCT00087490: Completed Phase 4 study of Skin/Soft Tissue Infections and Methicillin Resistant Staphylococcus Aureus (MRSA), sponsored by Pfizer.
NCT00087490 is a Phase 4 study of Skin/Soft Tissue Infections and Methicillin Resistant Staphylococcus Aureus (MRSA) that has completed, run by Pfizer. The registered enrollment target is 1,077 participants, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (108% higher). The trial reports 20 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00087490, a Phase 4 study of Skin/Soft Tissue Infections and Methicillin Resistant Staphylococcus Aureus (MRSA), has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 1,077 participants
- Enrollment target
- 20
- Study locations
Study Summary
To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects
Primary Outcome
Clinical response (CR) was based primarily on global assessment of clinical presentation of participant made by investigator at evaluation time point. At EOS, CR was evaluated as "success" (cure: resolution of clinical signs or (/) symptoms of infection when compared to baseline); "failure": persistence/progression of baseline signs/symptoms of infection after at least 2 days of treatment/development of new clinical findings consistent with active infection; "unknown": extenuating circumstances
Conditions Studied
Interventions
- DRUG linezolid
- DRUG vancomycin
Study Locations (20)
California
- Pfizer Investigational Site - Los Angeles
- Pfizer Investigational Site - Palm Springs
- Pfizer Investigational Site - Rancho Mirage
- Pfizer Investigational Site - San Pedro
- Pfizer Investigational Site - Santa Fe Springs
- Pfizer Investigational Site - Sylmar
- Pfizer Investigational Site - Torrance
- Pfizer Investigational Site - Torrance
- Pfizer Investigational Site - Torrance
Connecticut
- Pfizer Investigational Site - Hartford
- Pfizer Investigational Site - Hartford
- Pfizer Investigational Site - New Haven
- Pfizer Investigational Site - New Haven
Florida
- Pfizer Investigational Site - Atlantis
- Pfizer Investigational Site - Melbourne
- Pfizer Investigational Site - Miami
Colorado
- Pfizer Investigational Site - Denver
- Pfizer Investigational Site - Denver
Alabama
- Pfizer Investigational Site - Montgomery
Arizona
- Pfizer Investigational Site - Tucson
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,077 participants |
| Start Date | 2004-10 |
| Est. Completion | 2007-07 |
| Phase | Phase 4 |
What the finished NCT00087490 record still lists
NCT00087490 is an interventional study that assigns participants to a tested intervention. Its 1,077 participants enrollment target places it among the larger protocols in the corpus, above the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (108% higher).
The record links to 2 conditions, with Skin/Soft Tissue Infections appearing as the primary indexed condition, and to 2 interventions - of which linezolid is the first listed.
NCT00087490 names 20 study sites across 6 states, led by California, Connecticut, Florida.
Frequently Asked Questions
What is clinical trial NCT00087490 about?
NCT00087490 is a clinical study titled "Skin Structure Infections With Suspected or Proven Methicillin-Resistant Staphylococcus Aureus (MRSA)". To determine if linezolid is superior to vancomycin in the treatment of complicated skin and soft tissue infections due to MRSA in adult subjects
What is the current status of trial NCT00087490?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 1,077 participants. The study started on 2004-10. Estimated completion is 2007-07.
What conditions does trial NCT00087490 study?
This clinical trial studies the following conditions: Skin/Soft Tissue Infections, Methicillin Resistant Staphylococcus Aureus (MRSA).
What interventions are being tested in trial NCT00087490?
The interventions under investigation include: linezolid (DRUG), vancomycin (DRUG).
Who is sponsoring clinical trial NCT00087490?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00087490 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00087490's enrollment target sits among peer trials
1,077 66th of 2000 higher than 1,935 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT07084883 · 1,076 participants
Pivotal Trial of an Automated AI-based System for Early Diagnosis and Prediction of Late Age-related Macular Degeneration
- NCT06658808 · 1,075 participants · NA
Efficacy-Implementation Study for PC CARES in Rural Alaska
- NCT06074068 · 1,080 participants · NA
Father-Focused Intervention for Reducing Family Violence and Symptoms in Children
- NCT07213804 · 1,080 participants · Phase 3
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Part B) Ovarian Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia